JPWO2020166729A1 - T cell vaccine - Google Patents

Abstract

A vaccine against the pathogen in an allogeneic variant recipient individual, comprising donor-derived T cells that have been subjected to tissue-matching antigen expression suppression treatment, activation suppression treatment, and target antigen labeling treatment.

Description

The present invention relates to a T cell vaccine that multidisciplinarily induces neutralizing antibodies in lymphoid organs.

DST (donor specific blood transfusion / donor-specific blood transfusion) is a therapeutic method in which donor (allo) blood is administered to a host before organ transplantation to induce immune tolerance (Non-Patent Document 1: Clin Transplant 25: 317). , 2011). From the 1970s, when DST is performed before kidney transplantation, rejection is suppressed in a donor-specific manner. From clinical practice, antibodies against donor histocompatibility complex (MHC antigen) can be easily produced by a single blood transfusion. Although it has been reported, it is rarely done with the advent of immunosuppressive drugs that can easily treat rejection because of the possible side effects. Therefore, by what component in the allo antibody response (AFC response) blood, where, how happen, made antibodies is not yet elucidated or with what effects, including immunosuppression ..

The present inventor has so far analyzed the dynamics and functions of immunocompetent cells in the transplanted immune response of rats from the viewpoint of in vivo immunology at the organ level (Non-Patent Document 2: Cell Transplant 21: 581). , 2012; Non-Patent Document 3: Cell Transplant 19: 765, 2010; Non-Patent Document 4: Arch Histol Cyclo 73: 1, 2010; Non-Patent Document 5: Hepatology 56: 1532, 2012). In recent years, in order to elucidate the mechanism of immune response, immunohistochemistry and flow cytometry by multiple fluorescence immunostaining using thymidine analog EdU (Ethynyl deoxyuridine) using a rat model of GvH disease in an inbreeding system. A qualitative quantitative analysis method in which (FCM) is performed in parallel has been established (Non-Patent Document 6: Histochem Cell Biol 144: 195, 2015).

This method enables qualitative quantitative analysis of where and how much the cell-cell interaction of antigen phagocytosis presentation and immune proliferation response occur, and the mechanism of immune response can be analyzed. Therefore, when the immune response of the host was analyzed after DST as a preliminary experiment of this study, it was clarified that the allo AFC response occurs mainly in the spleen and that the antibody is against the donor type I MHC antigen (abbreviated as MHCI). As a result (Non-Patent Document 7: Int Immunol 30: 53, 2018), it was found that leukocytes, especially T cell fractions, were effective in the donor blood components, and other components such as erythrocytes were ineffective.

The allo-immune response is presented by direct sensitization in which donor antigen-presenting dendritic cells (DCs) directly associate with host T cells to present donor MHC antigens, and donor cell-derived MHC antigens are taken up by host DCs and presented. It is said to be caused by indirect sensitization (Non-Patent Document 8: Immunocity 14: 357, 2001). The AFC response (humoral immunity) is induced by Th2 helper T cells and follicular helper T cells (Follicular helper T cells / Tfh), and is a cytokine such as IL-4 and IL-10, and the GATA-3 gene, which is a transcription factor. It has been reported that the expression of is predominant (Non-Patent Document 9: Immunity 30: 324, 2009).

Since there is almost no DC in the blood, it is predicted that the antibody production response by DST is mainly related to the immune response by indirect sensitization in the spleen. Here, the immune response in the spleen occurs in the periarterial lymphocyte sheath (PALS / T cell region) in the white pulp, where DC is localized, and T and B cells are used for immune monitoring. It is known that many of them recirculate throughout the body, constantly migrating from blood into PALS and staying in PALS for a while, and T cells further associate with DC of PALS to confirm antigen information (Non-Patent Document 10). : Arch Histol Cyclo 73: 1,2010).

By the way, vaccines against pathogenic pathogens are usually administered intramuscularly or subcutaneously to induce the production of neutralizing antibodies mainly in the spleen. Therefore, when the spleen function is low or when the spleen is removed, the usual vaccine effect cannot be expected so much.

Clin Transplant 25: 317, 2011 Cell Transrant 21: 581,202 Cell Transrant 19: 765, 2010 ArchHistol System 73: 1,2010 Hepatology 56: 1532, 2012 Histochem Cell Biol 144: 195, 2015 Int Immunol 30:53,2018 Immunoty 14: 357, 2001 Immunoty 30: 324, 2009 Arch Histol System 73: 1,2010

Under the above circumstances, the development of a vaccine that induces neutralizing antibodies in multiple places has been desired.

As a result of diligent studies to solve the above problems, the present inventor labels allo T cells with a pathogen antigen, and inoculates the individual with the pathogen antigen, so that it is multidisciplinary not only in the spleen but also in the lymph nodes throughout the body. We have found that it induces a neutralizing antibody in the body, and have completed the present invention.

That is, the present invention is as follows.
(1) A vaccine against the pathogen antigen in allogeneic atypical recipient individuals, which comprises donor-derived T cells that have been subjected to tissue-compatible antigen expression suppression treatment, activation suppression treatment, and pathogen antigen labeling treatment.
(2) The vaccine according to (1), wherein the expression suppression treatment of the tissue-compatible antigen is RNA interference treatment with respect to the tissue-compatible antigen gene or knockout treatment of the gene.
(3) The vaccine according to (1) or (2), wherein the activation inhibitory treatment is an antimetabolite or DNA synthesis inhibitor treatment or an irradiation treatment.
(4) The vaccine according to any one of (1) to (3), wherein the pathogen is a virus or a bacterium.
(5) The vaccine according to (4), wherein the virus is an influenza virus.
(6) The vaccine according to any one of (1) to (5), which induces a neutralizing antibody in multiple places in lymphatic organs.

(7) A neutralizing antibody inducer in an allogeneic atypical recipient individual, which comprises donor-derived T cells that have been subjected to a tissue-compatible antigen expression suppression treatment, an activation suppression treatment, and a pathogen antigen labeling treatment.
(8) The neutralizing antibody inducer according to (7), wherein the expression suppression treatment of the tissue-compatible antigen is RNA interference treatment with respect to the tissue-compatible antigen gene or knockout treatment of the gene.
(9) The neutralizing antibody inducer according to (7) or (8), wherein the activation inhibitory treatment is an antimetabolite or a DNA synthesis inhibitor or an irradiation treatment.
(10) The neutralizing antibody inducer according to any one of (7) to (9), wherein the pathogen is a virus or a bacterium.
(11) The neutralizing antibody inducer according to (10), wherein the virus is influenza virus.
(12) The neutralizing antibody inducer according to any one of (7) to (11), which induces a neutralizing antibody in multiple places in lymphatic organs.

The present invention provides T cell vaccines and neutralizing antibody inducers. The T cell vaccine of the present invention is capable of inducing neutralizing antibodies in multiple places.

It is a figure which shows the experimental method of an Example. It is a schematic diagram of the staining method of the specific antibody-producing cell of an Example. It is a figure which shows the experimental result of Example 1. FIG. By semi-allo T cell administration (a system in which parent T cells are administered to a primary hybrid F1 recipient), a specific antibody against the labeled antigen phycoerythrin (PE) was detected in serum (left graph, red arrow), and a cervical lymph node section. Antibodies-producing cells (blue, right figure) appeared on the top, but no alloantibodies appeared (black arrow). On the other hand, in allo T cells, a large amount of allo antibody was produced, but the PE antibody titer was low.

The inventor somehow delivers the donor MHCI antigen after the donor T cells migrate to the splenic PALS after transfusion and associate with the host DC, where they most efficiently cause indirect sensitization, resulting in Th2 and Tfh. We conceived the hypothesis that induced and efficiently produced antigen-specific antibodies.

The present invention relates to vaccines and neutralizing antibody inducers against said pathogens in allogeneic recipient individuals, including donor-derived T cells that have been treated to suppress the expression of histocompatibility antigens, suppress activation and label pathogen antigens.
Allogeneic (allo) T cells, like autologous T cells, have the ability to recirculate and hematogenously migrate to lymphoid organs throughout the body, but efficiently streamline tissue-dwelling dendritic cells via T cell receptors. It has been found that when stimulated well, alloantibodies against the type I histocompatibility complex (MHC) of the T cells themselves are easily induced. This finding is different from autologous T cells.

Using the above findings, the present inventor labels allo T cells (T cells derived from a donor) with a pathogen antigen such as influenza, and administers this to a recipient other than the self (donor) to obtain only the spleen. We found that it induces neutralizing antibodies in multiple places in the lymph nodes. Since there are hundreds of lymph nodes in humans, the vaccine of the present invention capable of inducing neutralizing antibodies in systemic lymph nodes is highly efficient and can be used as a new concept vaccine.
Here, the T cells used in the present invention are collected from one individual. After the above treatment is applied to the T cells, the T cells are administered to another individual (that is, an individual of the same species and heterogeneity) that is the same species as the one individual. Therefore, the T cells used are referred to herein as "allo T cells".

In the present invention, T cells (allo T cells) collected from donor blood are subjected to a tissue-compatible antigen expression suppression treatment, an activation suppression treatment, and a pathogen antigen labeling treatment. Allo T cells treated in this way are administered to an allogeneic individual (recipient) different from the donor.

The tissue-compatible antigen expression suppression treatment means an alloantigen suppression treatment, and examples of the treatment for suppressing the expression of the tissue-compatible antigen include RNA interference treatment for the tissue-compatible antigen gene or knockout treatment of the gene. Can be mentioned.
Synthetic nucleic acid molecules that can suppress gene expression by RNA interference (RNAi) include, for example, siRNA (small interfering RNA), microRNA (miRNA) and shRNA (shorthairpin RNA).

siRNA can be designed based on standards well known in the art. For example, the target segment of the mRNA of the target tissue-compatible antigen gene can be preferably a continuous segment of 15 to 30 bases starting with AA, TA, GA or CA, preferably 19 to 25 bases. The GC ratio of siRNA is 30-70%, preferably 35-55%.
siRNA is produced as a single-stranded hairpin RNA molecule that folds over its own nucleic acid to produce a double-stranded portion.

The siRNA molecule can be obtained by conventional chemical synthesis, but it can also be biologically generated using an expression vector containing sense and antisense siRNA sequences.
In order to introduce siRNA into cells, a method of ligating siRNA synthesized in vitro to plasmid DNA and introducing it into cells, a method of annealing a double-stranded RNA, or the like can be adopted.

shRNA is an RNA molecule having a stem-loop structure in which a part of a single strand has a complementary strand formed with another region. Therefore, shRNA is designed so that a part thereof forms a stem-loop structure. For example, if the sequence of a certain region is sequence A and the complementary strand to sequence A is sequence B, the sequences A, spacers, and sequence B are linked in this order so that they are present in one RNA strand, and the whole is linked. It is designed to have a length of 45 to 60 bases. Sequence A is a sequence of a part of a region of a target tissue-compatible antigen gene, and the target region is not particularly limited, and any region can be a candidate. The length of the sequence A is 19 to 25 bases, preferably 19 to 21 bases.

Furthermore, the present invention can suppress the expression of the above gene using microRNA (miRNA). MiRNA is a single-stranded RNA having a length of about 20 to 25 bases existing in a cell, and is a kind of ncRNA (non-coding RNA) considered to have a function of regulating the expression of other genes. .. miRNAs exist as nucleic acids that form a hairpin structure that is processed when transcribed into RNA and suppresses the expression of target sequences.
Since miRNA is also an inhibitory nucleic acid based on RNAi, it can be designed and synthesized according to shRNA or siRNA.

Further, in the present invention, a tissue-compatible antigen gene can be knocked out. Examples of the knockout method include, but are not limited to, knockout by CRISPR / Cas9.
The siRNA treatment or the gene knockout treatment with CRISPR / Cas9 can be performed by the method described in the publicly known literature (Cancer Cell Int. 13: 112, 2013; Cancer Cancer Res 23: 2255, 2017).

The T cell activation inhibitory treatment means a treatment for removing the risk of developing GvH disease of T cells, and examples of the activation inhibitory treatment include antimetabolite or DNA synthesis inhibitor treatment or irradiation treatment. Be done. The antimetabolites and DNA synthesis inhibitors that can be used in the present invention, and irradiation are illustrated below.

<Antimetabolite or DNA synthesis inhibitor>
Folic acid analogs: methotrexate, pemetrexed, pralatrexate, etc. Purine analogs: mercaptopurine, thioguanine, cladribine, fludarabin, etc. Alkylating agents: cyclophosphamide, merphalan, thiotepa, busulfan, etc. Platinum preparations: cisplatin, iproplatin, carboplatin, etc.

The amount of antimetabolite or DNA synthesis inhibitor, 37 ° C. 30 min with mitomycin C if 20μg / 5x10 ⁷ / ml treatment, others use a proper amount. This treatment can be carried out by the method described in the publicly known literature (Hepatology 56: 1532, 2012).

<Irradiation treatment>
X-rays, gamma rays radiation amount, 10 ⁸ cells per 10～50Gy, preferably 15 Gy. These treatments can be performed by the method described in the publicly known literature (Arch Pathol Lab Med 142: 662, 2018).

In the present invention, the pathogen used as an antigen is not particularly limited, and examples thereof include viruses, bacteria, and protozoans. For antigen labeling, a gene vector of the target antigen is prepared and a gene transfer technique into T cells is used.

Examples of the virus include influenza virus, hepatitis virus, herpes zoster, measles / rubella, papilloma (HPV), human immunodeficiency (HIV) virus and the like.
Examples of the bacterium include Streptococcus pneumoniae, Meningococcus, Diphtheria, Clostridium tetani, Bordetella pertussis, and tuberculosis.
Examples of protozoans include malaria.

Alo T cell vaccines are prepared by treating donor-derived T cells with (a) tissue-compatible antigen expression suppression treatment, (b) activation suppression treatment, and (c) pathogen antigen labeling treatment, in that order. It is not particularly limited. The above processing may be performed in the order of (a), (b), (c), or may be another order. Regarding (c), a pathogen antigen is bound to an antibody that specifically recognizes T cells, such as an anti-CD4 antibody, to prepare a complex of the antibody and the pathogen antigen, and this is bound to a donor T cell. You can also.

By such treatment, the original function of alloimmunity that causes GvH disease and alloantibody production induction in the recipient of donor T cells (allo T cells) is lost, but a new function of antigen transport ability is acquired. It becomes. As a result, cells specialized in antigen transport capable of delivering pathogen antigens to recipient dendritic cells of lymphatic organs throughout the body without causing an allo-immune response were produced. This cell can be administered to any recipient with different MHC, and in that sense, it can be regarded as a "standardized" allo-T cell. The standardized allo T cells can be used as a relatively safe and versatile entirely new type of vaccine.

The allo T cells treated as described above are administered to a target individual of allogeneic strain, which is a recipient. This makes it possible to induce neutralizing antibodies against labeled antigens in multiple places in lymphoid organs in allogeneic individuals.
The vaccine of the present invention can also be used as a pharmaceutical composition for diseases related to the antigen, depending on the antigen used. The pharmaceutical composition of the present invention can be administered depending on the form of a parenteral administration agent such as an injection. Preferably, in addition to intravenous injection, local injection into the abdominal cavity or the like is exemplified.

Examples of the administration method include intravenous administration and intraperitoneal administration.
The dose is appropriately selected depending on the route of administration, the subject of administration, the age, weight, sex, symptoms and other conditions of the patient. The daily dose of allo T cells used as a vaccine, intravenous administration in the case of 10 ⁷ / ml to 10 ⁹ cells / ml, preferably 5x10 ⁷ / Ml～5x10 about ⁸ / ml, It can be administered once a day or in several divided doses.
The vaccine of the present invention can induce neutralizing antibodies systemically and in multiple places not only in humans with normal spleen function but also in humans with reduced or splenectomy.
Therefore, the allo T cells of the present invention can be used as a neutralizing antibody inducer.

Hereinafter, the present invention will be described in more detail with reference to Examples. However, the scope of the present invention is not limited to these examples.
[Example 1]

Method: T cells of parent rats are labeled with FITC itself as an antigen or phycoerythrin bound to an anti-CD4 antibody, treated with mitomycin C, and then intravenously administered to splenectomized F1 hybrid F1 rats, and various lymph nodes are administered 7 days later. Nodes and serum were collected.
Lymph nodes visualized specific antibody-producing cells on the sections, and serum was quantified for specific antibodies with a flow cytometer (Fig. 1).
That is, on the frozen section, first, normal mouse IgG labeled with phycoerythrin or FITC was bound to the antibody presence site of antigen-specific AFC. Next, an enzyme (alkaline phosphatase) -labeled anti-mouse IgG was reacted, and then the enzyme was colored and visualized (Fig. 2).

As a result, specific antibody-producing cells were detected in a plurality of lymph nodes, and specific antibodies were observed in the serum, but neither the proliferative response of the donor cells nor the allo-MHC antibody was detected. On the other hand, antigen-labeled autologous T cells did not induce an antibody response (Fig. 3).

In the case of a semi-allo combination in which paternal (A) T cells were administered to F1 rats, F1 (B xA) co-expresses the parents' MHCI and therefore cannot recognize the MHC (A) of donor T cells. Therefore, although no reaction to MHCI occurs, donor T cells recognize maternal MHC (B system) expressed on tissue-dwelling dendritic cells via T cell receptors and interact with them to cause dendritic cells. As a result, it is considered that antibody production against the labeled antigen could be induced.
Since donor T cells whose MHCI expression is suppressed by siRNA or the like should not theoretically cause a reaction to MHCI, it can be said that the F1 rat system is a model similar to the system using siRNA. On the other hand, since autologous T cells cannot induce an antibody response, it is a necessary condition in the present invention to use allo T cells.

Claims (12)

A vaccine against the pathogen antigen in an allogeneic variant recipient individual, comprising donor-derived T cells that have been treated to suppress the expression of a tissue-compatible antigen, to suppress activation, and to be labeled with a pathogen antigen. The vaccine according to claim 1, wherein the treatment for suppressing the expression of a tissue-compatible antigen is an RNA interference treatment for the tissue-compatible antigen gene or a knockout treatment for the gene. The vaccine according to claim 1 or 2, wherein the activation inhibitory treatment is an antimetabolite or DNA synthesis inhibitor treatment or an irradiation treatment. The vaccine according to any one of claims 1 to 3, wherein the pathogen is a virus or a bacterium. The vaccine according to claim 4, wherein the virus is an influenza virus. The vaccine according to any one of claims 1 to 5, which induces a neutralizing antibody in multiple places in lymphatic organs. Neutralizing antibody inducer in allogeneic atypical recipient individuals, including donor-derived T cells that have been subjected to tissue-matching antigen expression suppression treatment, activation suppression treatment, and pathogen antigen labeling treatment. The neutralizing antibody inducer according to claim 7, wherein the expression suppression treatment of the tissue-compatible antigen is RNA interference treatment with respect to the tissue-compatible antigen gene or knockout treatment of the gene. The neutralizing antibody inducer according to claim 7 or 8, wherein the activation inhibitory treatment is an antimetabolite or a DNA synthesis inhibitor or an irradiation treatment. The neutralizing antibody inducer according to any one of claims 7 to 9, wherein the pathogen is a virus or a bacterium. The neutralizing antibody inducer according to claim 10, wherein the virus is an influenza virus. The neutralizing antibody inducer according to any one of claims 7 to 11, which induces a neutralizing antibody in multiple places in lymphatic organs.